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LETTERS TO THE EDITORS
Transplant Livers in Wilson’s Disease for Hepatic,
not Neurologic, Indications
To the Editors:
We are very concerned by the report entitled, “Liver
Transplantation for Wilson’s Disease: A Single-Center
Experience” which appeared in your journal (vol 5, pp
467-474, November 1999).1 Throughout the article,
the authors infer, and in some places outright claim,
that orthoptic liver transplantation (OLT) is an effec-
tive, and perhaps advantageous, way to treat the neuro-
logical symptoms of Wilson’s disease. For example, the
last sentence of the abstract: “Earlier transplantation in
patients with an unsatisfactory response to medical
treatment may prevent irreversible neurological de-
terioration and less satisfactory improvement after
OLT.”
This statement leads to a risk that OLT will be used
to manage neurological symptoms; in our opinion, this
would be a serious mistake. The authors are apparently
unaware that OLT is simply another anticopper ther-
apy as far as neurological symptoms, other than hepatic
encephalopathy, are concerned. The risks of morbidity
and mortality from needless transplantation resulting
from such assertions are of concern.
The neurological symptoms of Wilson’s disease are
caused by copper toxicity in specific areas of the brain,
areas that coordinate movement.2,3 Any approach to
reducing copper levels below toxic levels will stop fur-
ther copper damage at that point, but symptoms arising
from that damage will not begin improving until 5 to 6
months later, and will continue to improve for another
18 months (24 months from initiation of anticopper
therapy).2,4,5 In other words, anticopper drugs and
OLT have no direct effect on the neurological symp-
toms, they only control copper. The brain has to repair
itself, and will, slowly, to the extent that damage isn’t
irreversible.
The authors speak of “an unsatisfactory response to
medical treatment” and suggest that “earlier transplan-
tation” “may prevent irreversible neurological deterio-
ration.” If “an unsatisfactory response to medical treat-
ment” means the failure to respond in the first 6
months, this is simply the natural history of the repair of
the injury. None of the brain damage from copper
toxicity will have repaired itself enough to allow symp-
tomatic improvement during the first 5 to 6 months of
anticopper therapy.5-7 It is not valid to claim an unsat-
isfactory response to medical therapy during this pe-
riod. Yet, if they are transplanted during this period,
they will likely then improve (being in the 6- to 18-
month window when neurological improvement oc-
curs), appearing to justify the authors’ concept that
OLT has done something beyond what anticopper
drugs are able to do. If “an unsatisfactory response to
medical treatment” means the persistence of symptoms,
sometimes quite disabling, after 2 years of therapy,
these symptoms are permanent and will not be helped
by any anticopper therapy, including OLT.2,4-7 The
authors seemed to have bumped into this phenomenon
in some of their patients, but attribute the problem to
patients not receiving transplants early enough, rather
than to some patients simply having relatively severe
and permanent damage.
There is one caveat to this discussion, and that is, we
are not talking about using penicillamine for initial
treatment of neurologically presenting Wilson’s disease
patients. Penicillamine should never be used in this
setting because it causes 50% of patients to get worse
neurologically, and 25% never recover.8
The great risk from the authors’ report is that some
physicians, following their advice, are going to have
patients undergo transplants for the wrong indications
and, therefore, needlessly. For the last 20 years, one of
us (G.J.B.) has struggled to improve the therapy of
Wilson’s disease and has seen and treated 250 patients,
100 of whom were referred for initial neurological treat-
ment. Based on that experience, we offer the following
guidelines:
1. Never transplant in Wilson’s disease because of the
neurological symptoms related to copper toxicity.
Anything OLT can do for neurological symptoms,
anticopper drugs can also do without the up-to-30%
long-term mortality and extensive morbidity.
2. Transplant only in Wilson’s disease based on a liver
disease status in which transplantation, versus med-
ical therapy, represents the most favorable option for
the patient. Obviously, fulminant hepatic failure
falls into this category. But even in patients with
cirrhosis with mild hepatic decompensation, such as
ascites, mild hyperbilirubinemia, and portal hyper-
tension, we are often able to treat the patient medi-
cally, the liver disease is partially reversible, and the
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patients do well. Borderline cases of more pro-
nounced hepatic decompensation can be difficult. If
they go sour, hepatic transplantation sometimes has
to be performed under less than ideal circumstances,
if a liver is available. We use the prognostic index of
Nazer et al9 to help triage these patients.
3. Don’t forget that patients with the liver disease of
Wilson’s generally may have a more favorable prog-
nosis with medical therapy than alcoholic and viral
hepatitis patients, in that there is specific and uni-
formly effective treatment, and a substantial hepatic
recovery after anticopper therapy (generally between
4 and 12 months after therapy initiation).
4. Save livers for people who really need them. Because
donor livers are in such short supply and the demand
for transplantation is growing at an alarming rate,
the decision to perform transplantation on a patient
for neurologic indications who would fare as well or
better with medical therapy as surgical therapy not
only does that individual a disservice, but actually
means that someone else who could have been
helped may die needlessly.
5. As with any condition, the optimal treatment of
Wilson’s disease requires specific experience and ex-
pertise, which, because of the rarity of the disease,
will not be available at every medical center. Some
guidance can be obtained through the Wilson’s Dis-
ease Association web site, www.wilsonsdisease.org.
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After reading the long and acrimonious letter of Drs
Brewer and Askari, we are not clear as to its purpose
apart from indulging in self-citation. The authors did
not seem to realize that the indication for liver trans-
plantation in all of our 45 patients was fulminant, sub-
acute, or chronic hepatic failure. We had no instance of
Wilson’s disease presenting solely with neurological
symptoms as an indication for liver transplantation in
our 45 patients. Furthermore, we said in our publi-
cation that the use of liver transplantation is controver-
sial for patients presenting only with neurological
symptoms. Fourteen of our patients, apart from their
hepatic manifestations, also had Wilsonian neurologi-
cal manifestations. Ten of these patients showed signif-
icant neurological improvement after liver transplanta-
tion.
The authors also seem to be unaware of several pub-
lications1-4 in which liver transplantation has been used
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for patients presenting only with severe neurological
manifestations due to Wilson’s disease and failed med-
ical treatment, with significant recovery.
Lastly, we consider it irresponsible to conclude from
our report that liver transplantation should be offered as
a first line of treatment to patients with hepatic or
neurological Wilson’s disease, with the exception of
patients with Wilson fulminant hepatic failure.
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